Covance is one of the world's largest and most comprehensive drug development services companies with more than 10,000 employees in 60 countries.
Covance is one of the world's largest and most comprehensive drug development services companies with more than 10,000 employees in 60 countries. Customized and committed to clients large or small, through its discovery, nonclinical, clinical, CMC and commercialization services, Covance has helped pharmaceutical and biotech companies develop one-third of all prescription medicines in the market today.
This is a focused introduction on the Covance CMC development capabilities for small and large molecules.
Small Molecule Chemistry, Manufacturing & Controls Development Services (CMC)
Covance offers a comprehensive and integrated set of CMC Pharmaceutical Development Services, including API development and supply, preformulation and formulation development, analytical and stability, and regulatory documentation services.
Built on the optimal combination of top-five pharma expertise, experience and facilities, and decades of excellent client service record, Covance is committed to helping pharmaceutical companies reduce time in development and improve molecule hit rate.
Biotechnology Services: Large Molecule CMC Analytical and Testing Services
With over 250 different biomolecules successfully supported annually, Covance now offers the most comprehensive biotechnology service in the industry.
Our experience covers a wide range of biomolecules, including recombinant proteins, monoclonal antibodies, vaccines, blood products, gene therapy products and more. Our capabilities include protein analytical chemistry, immunocharacterization, cell banking, biosafety testing, viral clearance, bioassay studies, molecular biology, stability and release, biomanufacturing support and more.
You can choose to work with us on individual projects, milestone-based packages or full drug development solutions, whichever best fit your needs.
Drug Solutions Podcast: Novel Drug Delivery Approaches: Refining AAV Vector Deliveries
May 30th 2025In this podcast episode, we discuss novel approaches to drug delivery, specifically regarding adeno-associated virus (AAV) vectors, as viewed by two industry experts who recently exhibited at the annual ASGCT meeting.
Transformations in Drug Development for Cell and Gene Therapies
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
A Novel, Enhanced, and Sustainable Approach to Audit Trail Review
July 4th 2025Eli Lilly and Company developed an innovative and sustainable approach to audit trail review (ATR) aimed at reducing the ATR burden while adhering to regulatory expectations and data integrity (DI) principles. The process has transformed employees' understanding of ATR and complemented the DI by design approach, leading to better system designs that meet expected controls and reduce non-value-added data reviews.